When FDA inspectors do visit drug plants in India and other countries, they sometimes find egregious violations.
As COVID-19 swept across the globe in early 2020, the Food and Drug Administration (FDA) pulled most of its safety inspectors from the field, creating a massive backlog of uninspected pharmaceutical plants in the U.S. and overseas.
When FDA inspectors do visit drug plants in India and other countries, they sometimes find egregious violations.
As COVID-19 swept across the globe in early 2020, the Food and Drug Administration (FDA) pulled most of its safety inspectors from the field, creating a massive backlog of uninspected pharmaceutical plants in the U.S. and overseas. News
